Inspire Veterinary Faces Nasdaq Delisting Amidst Dilutive Resale Offering

TL;DR

**IVPR is a high-risk bet, facing delisting and massive dilution from selling stockholders, making it a strong sell.**

AI Summary

Inspire Veterinary Partners, Inc. (IVPR) is registering 46,419,092 shares of Class A common stock for resale by selling stockholders, comprising 26,194,092 shares from Series B preferred stock conversion, 7,725,000 shares from warrant exercises at $1.00 per share, and 12,500,000 shares from conversion of $1,250,000 in promissory notes issued to Target Capital 1, LLC. The company's stock price was $0.12 per share on November 28, 2025, and it received a Nasdaq delisting notice on November 13, 2025, for failing to meet the minimum bid price requirement, with a hearing scheduled for January 13, 2026. IVPR recently redeemed 2,027 shares of Series B Preferred Stock for approximately $2.7 million on December 1, 2025. On November 5, 2025, the company issued Senior Convertible Promissory Notes totaling $357,142.86 to Keystone Capital Partners, LLC and Seven Knots, LLC, with a 30% original issue discount, bearing 10% annual interest and maturing on August 5, 2026. The conversion price for these notes is 90% of the lowest sale price over 20 trading days, and the company will not receive any proceeds from the current offering.

Why It Matters

This S-1/A filing signals significant potential dilution for existing IVPR investors, as 46,419,092 shares are being registered for resale, nearly doubling the outstanding Class A common stock from 38,567,465 to 84,986,557 shares. The Nasdaq delisting notice, issued on November 13, 2025, due to a sub-$1.00 bid price ($0.12 on November 28, 2025) and previous reverse stock splits, creates substantial uncertainty for the company's market access and investor confidence. Competitors in the veterinary services sector, such as Mars Petcare and VCA Animal Hospitals, operate with significantly more stable financial profiles, highlighting IVPR's precarious position. Employees face potential instability given the company's financial struggles and delisting threat, while customers may see no immediate impact but long-term operational risks.

Risk Assessment

Risk Level: high — The risk level is high due to the Nasdaq delisting notice received on November 13, 2025, for failing to meet the minimum bid price requirement, with the stock trading at $0.12 per share on November 28, 2025. Furthermore, the offering of 46,419,092 shares for resale by selling stockholders represents a potential dilution of over 120% to the 38,567,465 shares outstanding immediately prior to this offering, significantly increasing supply without new capital for the company.

Analyst Insight

Investors should consider divesting IVPR shares due to the imminent delisting threat from Nasdaq and the substantial dilution from the 46,419,092 shares being registered for resale. The company's inability to maintain a compliant bid price and its reliance on dilutive financing mechanisms suggest a challenging path forward.

Key Numbers

• 46,419,092 shares — Class A Common Stock offered by Selling Stockholders (Represents potential dilution for existing shareholders)
• $0.12 — Last reported sale price of Common Stock (On November 28, 2025, contributing to Nasdaq delisting)
• 38,567,465 shares — Class A common stock outstanding immediately prior to this offering (Baseline for calculating potential dilution)
• 84,986,557 shares — Class A common stock outstanding immediately after this offering (Total shares after potential conversion and exercise by selling stockholders)
• $1.00 — Exercise price of warrants (For 7,725,000 shares issued to Private Placement investors)
• $1,250,000 — Aggregate principal amount of promissory notes (Issued to Target Capital 1, LLC, convertible into 12,500,000 shares)
• 2,027 shares — Series B Preferred Stock redeemed (For approximately $2.7 million on December 1, 2025)
• $357,142.86 — Total principal amount of Senior Convertible Promissory Notes (Issued to Keystone Capital Partners, LLC and Seven Knots, LLC on November 5, 2025)
• 10% — Interest rate on Senior Convertible Promissory Notes (Payable monthly, maturing August 5, 2026)
• 90% — Conversion price discount for Senior Convertible Promissory Notes (Of the lowest sale price over 20 consecutive trading days)

Key Players & Entities

• INSPIRE VETERINARY PARTNERS, INC. (company) — Registrant and veterinary hospital operator
• Nasdaq Capital Market (regulator) — Stock exchange where IVPR is listed and facing delisting
• Target Capital 1, LLC (company) — Holder of promissory notes convertible into 12,500,000 shares
• Keystone Capital Partners, LLC (company) — Investor in Senior Convertible Promissory Notes
• Seven Knots, LLC (company) — Investor in Senior Convertible Promissory Notes and existing equity line of credit provider
• Kimball Carr (person) — Chair, President and Chief Executive Officer
• Spartan Capital Securities, LLC (company) — Underwriter in initial public offering
• Dragon Dynamic Catalytic Bridge SAC Fund (company) — Warrant holder
• 622 Capital LLC (company) — Warrant holder
• Sean Klein (person) — Contact for copies of filing

FAQ

Risk Factors

• Nasdaq Delisting Risk [high — market]: The company received a Nasdaq delisting notice on November 13, 2025, for failing to meet the minimum bid price requirement. A hearing is scheduled for January 13, 2026. This poses a significant risk to liquidity and investor confidence.
• Significant Dilution from Resale Offering [high — financial]: The registration of 46,419,092 shares for resale by selling stockholders, including conversions from preferred stock, warrant exercises, and promissory notes, represents a substantial increase in outstanding shares. This could significantly dilute existing shareholders' ownership.
• Convertible Note and Warrant Conversion Risk [high — financial]: The conversion of $1,250,000 in promissory notes and the exercise of 7,725,000 warrants at $1.00 per share will result in the issuance of millions of new shares. The conversion price for Senior Convertible Promissory Notes is set at 90% of the lowest sale price over 20 trading days, potentially leading to further dilution at low stock prices.
• Redemption of Series B Preferred Stock [medium — financial]: The company redeemed 2,027 shares of Series B Preferred Stock for approximately $2.7 million on December 1, 2025. This significant cash outflow impacts the company's liquidity and financial flexibility.
• High Interest on Convertible Notes [medium — financial]: Senior Convertible Promissory Notes issued on November 5, 2025, carry a 10% annual interest rate and a 30% original issue discount. These terms indicate potentially costly financing for the company.
• Dependence on Future Financing [medium — operational]: The company's ability to continue operations and meet its obligations, including the maturity of notes on August 5, 2026, may depend on its ability to secure additional financing. The current offering does not provide proceeds to the company.

Industry Context

The veterinary services industry is generally considered stable, driven by consistent demand for pet care. However, the market is becoming increasingly consolidated with large corporate consolidators acquiring independent practices. Companies like Inspire Veterinary Partners operate within this evolving landscape, facing competition from both independent clinics and larger groups.

Regulatory Implications

The company is subject to standard SEC regulations for public filings and Nasdaq listing rules. The recent delisting notice highlights the critical importance of maintaining compliance with Nasdaq's minimum bid price requirements to ensure continued trading on the exchange.

What Investors Should Do

1. Monitor Nasdaq Delisting Hearing Outcome
2. Assess Dilution Impact
3. Evaluate Company's Path to Profitability and Compliance
4. Scrutinize Convertible Debt Terms

Key Dates

• 2025-11-13: Received Nasdaq Delisting Notice — Indicates failure to meet minimum bid price requirements, raising concerns about stock liquidity and market perception.
• 2025-11-28: Last reported sale price of Common Stock — The stock price was $0.12, highlighting the bid price deficiency that led to the delisting notice.
• 2025-11-05: Issued Senior Convertible Promissory Notes — Raised $357,142.86 with a 10% interest rate and 30% OID, convertible at a discount, indicating current financing needs.
• 2025-12-01: Redeemed Series B Preferred Stock — The company spent approximately $2.7 million to redeem 2,027 shares, impacting cash reserves.
• 2026-01-13: Nasdaq Delisting Hearing — A critical date to determine the company's listing status on Nasdaq.
• 2026-08-05: Maturity Date for Senior Convertible Promissory Notes — The company must address these obligations by this date, potentially through refinancing or conversion.

Glossary

Series B Preferred Stock

A class of stock with preferential rights over common stock, often including liquidation preferences or dividend rights. In this case, it was convertible into Class A common stock. (A significant portion of the shares being registered for resale originated from the conversion of Series B preferred stock.)

Warrants

Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a predetermined price (exercise price) before a specified expiration date. (7,725,000 shares are being registered for resale due to the exercise of warrants at a $1.00 exercise price.)

Promissory Notes

A written promise by one party (the note issuer) to pay a specific sum of money to another party (the note holder) on demand or at a specified future date. ($1,250,000 in promissory notes issued to Target Capital 1, LLC are convertible into 12,500,000 shares of Class A common stock.)

Original Issue Discount (OID)

The difference between the face amount of a debt instrument and the issue price, when the issue price is less than the face amount. It is treated as interest income over the life of the instrument. (Senior Convertible Promissory Notes were issued with a 30% OID, indicating a significant discount to their face value.)

Selling Stockholders

Existing shareholders who are offering to sell their shares of the company's stock in a public offering. The company does not receive proceeds from these sales. (The current S-1/A filing is primarily to register shares for resale by these stockholders, not to raise capital for the company.)

Class A Common Stock

The basic form of ownership in a corporation, typically carrying voting rights. In this case, it's the stock being registered for resale. (The shares being registered for resale are all Class A common stock.)

Year-Over-Year Comparison

This S-1/A filing indicates a significant shift from a capital-raising event to a resale registration by existing stockholders. Key metrics like revenue, net income, and margins are not provided in this excerpt, making a direct comparison difficult. However, the company's recent receipt of a Nasdaq delisting notice and the substantial number of shares being registered for resale suggest a deteriorating financial position and increased risk compared to any prior period where the company might have been in better standing.

Key Financial Figures

• $0.0001 — 092 shares of our Class A common stock, $0.0001 par value per share, (the "Class A comm
• $1.00 — se of warrants (at an exercise price of $1.00 per share), issued to investors in the
• $1,250,000 — d, in the aggregate principal amount of $1,250,000 issued to Target Capital 1, LLC ("Targe
• $0.12 — apital Market on November 28, 2025, was $0.12 per share. We are registering the sha
• $2.7 million — ies B Preferred Stock for approximately $2.7 million. Senior Convertible Promissory Notes
• $178,571.43 — tors"), each in the principal amount of $178,571.43 with an original issue discount of 30%
• $125,000 — hat the purchase price of each note was $125,000 (each a "Note" and together, the "Notes
• $1,000,000 — roceeds to the Company of not less than $1,000,000, and excludes the conversion of the Not
• $6,000 — to the Company at an exercise price of $6,000 per share and have an expiration date o
• $11,000 — public offering at an exercise price of $11,000 per share and have an expiration date o
• $10,000 — 622 Capital LLC at an exercise price of $10,000 per share and have an expiration date o
• $233.75 — public offering at an exercise price of $233.75 per share and have an expiration date o
• $17.00 — stock options, at an exercise price of $17.00 per share. The stock options were grant
• $1.71 — stock options, at an exercise price of $1.71 per share. The stock options were grant
• $1.62 — stock options, at an exercise price of $1.62 per share. The stock options were grant

Filing Documents

• ea0267069-s1a1_inspire.htm (S-1/A) — 3455KB
• ea026706901ex4-6_inspire.htm (EX-4.6) — 193KB
• ea026706901ex10-24_inspire.htm (EX-10.24) — 182KB
• ea026706901ex23-1_inspire.htm (EX-23.1) — 2KB
• image_001.jpg (GRAPHIC) — 4KB
• image_002.jpg (GRAPHIC) — 83KB
• image_003.jpg (GRAPHIC) — 73KB
• 0001213900-25-118818.txt ( ) — 15978KB
• ivp-20250930.xsd (EX-101.SCH) — 119KB
• ivp-20250930_cal.xml (EX-101.CAL) — 91KB
• ivp-20250930_def.xml (EX-101.DEF) — 664KB
• ivp-20250930_lab.xml (EX-101.LAB) — 1029KB
• ivp-20250930_pre.xml (EX-101.PRE) — 700KB
• ea0267069-s1a1_inspire_htm.xml (XML) — 2034KB

Use of Proceeds

Use of Proceeds 25

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Our Business 61 Management and Board of Directors 66 Executive and Director Compensation 73

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 80 Certain Relationships and Related Party Transactions 82

Description of Capital Stock

Description of Capital Stock 84 Private Placement of Series B Preferred Stock, Warrants and Convertible Notes 89 Selling Stockholders 92 Plan of Distribution 95 Legal Matters 97 Experts 97 Where You Can Find More Information 97 Index to Financial Statement F-1 You should rely only on the information contained in this prospectus. Neither we, nor the Selling Stockholders have authorized anyone to provide information different from that contained in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, shares of Common Stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our Common Stock. i PROSPECTUS SUMMARY Inspire Veterinary owns and operates veterinary hospitals throughout the United States. The Company specializes in small animal general practice hospitals which serve all manner of companion pets, emphasizing canine and feline breeds and including equine care. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. The Company completed its initial public offering on August 31, 2023 and its shares of Class A common stock are traded on The Nasdaq Capital Market ("Nasdaq") under the symbol "IVP." As of the date of this prospectus, the Company currently has fourteen veterinary hospitals located in nine states. Inspire Veterinary has expanded and plans to further expand through acquisitions of existing hospitals which have the financial track record, marketplace advantages and future growth potential. Because the Company leverages a leadership and support structure which is distributed throughout the United States, acquisitions are not centralized to one geographic area. Services provided at the Company's h

Use of proceeds

Use of proceeds We will not receive any proceeds from the sale of shares of our Common Stock by the Selling Stockholders

Risk factors

Risk factors Investing in our securities involves a high degree of risk. See "Risk Factors" beginning on page 9 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our securities. Nasdaq symbol for our Class A common stock "IVP" The number of shares of our Common Stock that will be outstanding immediately after this offering excludes the following: 20 shares of Common Stock issued to our Chair, President and Chief Executive Officer Kimball Carr in connection with his personal guaranty of certain loans to the Company at an exercise price of $6,000 per share and have an expiration date of January 1, 2028; 32 shares of Common Stock that are issuable upon exercise of warrants issued in connection with the initial public offering and held by Spartan Capital Securities, LLC, the underwriter in our initial public offering at an exercise price of $11,000 per share and have an expiration date of August 29, 2030; 332 shares of Common Stock that are issuable upon exercise of the warrants held by Target Capital 1, LLC, Dragon Dynamic Catalytic Bridge SAC Fund and 622 Capital LLC at an exercise price of $10,000 per share and have an expiration date of June 30, 2028; 6 753 shares of Common Stock that are issuable upon exercise of warrants issued in connection with the public offering in February 2024 and held by Spartan Capital Securities, LLC, the underwriter in our public offering at an exercise price of $233.75 per share and have an expiration date of August 16, 2028; 6,741 shares of Common Stock that are issuable upon exercise of outstanding stock options, at an exercise price of $17.00 per share. The stock options were granted and immediately vested on September 26, 2024 and have an expiration date of September 26, 2034; 58,480 shares of Common Stock that are issuable upon exercise of outstanding stock options, at an exercise price of $1.71 per share. The stock option

View Full Filing

View this S-1/A filing on SEC EDGAR